Metabolic syndrome among pre- and post-menopausal rural women in Bangladesh: result from a population-based study

Subrina Jesmin1,2*, AM Shahidul Islam1,2, Shamima Akter1,2, Md Majedul Islam1,2, Sayeeda Nusrat Sultana1,2, Naoto Yamaguchi1, Osamu Okazaki2, Masao Moroi2, Michiaki Hiroe2, Sosuke Kimura2, Tetsu Watanabe3, Kawano Saturo4 and Taro Mizutani4

Abstract

Background: Prevalence of non-communicable diseases are a challenging problems among menopausal women specially in a least developed country like Bangladesh, where majority of women suffering from at least one chronic disease after menopausal age. So, the main objective of this study was to determine the prevalence of metabolic syndrome and related risk factors in Bangladeshi pre- and post-menopausal women living in the rural setting.

Methods: This study is based on a community based cross-sectional survey among 1802 rural women aged ≥15 years. Metabolic syndrome was defined according to the criteria of NCEP-ATP III. Logistic regression was used to estimate the association between menopausal status and metabolic syndrome and its components.

Results: Metabolic syndrome was presented in 25.6% respondents and it was more prevalent among post-menopausal (39.3%) as compared to pre-menopausal (16.8%) women. Logistic regression analysis reveals that prevalence of metabolic syndrome was 1.78 times higher in post-menopausal women than pre-menopausal women (P = 0.001). Prevalence of high blood pressure, elevated fasting blood glucose, and high triglyceride were significantly higher in post-menopausal women than pre-menopausal women (P < 0.05). However, prevalence of low high-density lipoprotein cholesterol was significantly lower in post-menopausal women than pre-menopausal women (P < 0.001).

Conclusions: Metabolic syndrome seems to be a major health problem among post-menopausal women in many developing countries like Bangladesh and proper policy emphasis should be given on its prevention and control.

Keywords: Metabolic syndrome, Pre-menopausal women, Post-menopausal women, Bangladesh

Background

The prevalence of chronic non-communicable diseases such as cardiovascular diseases and type 2 diabetes is increasing significantly in Bangladesh [1]. This increase is observed not only in the urban areas but also in the rural population, especially rural women in Bangladesh seems to be more vulnerable who are mostly poor and physically active [2]. The metabolic syndrome (MS) is a cluster of risk factors including obesity, glucose intolerance, dyslipidemia, and hypertension that increase the risk for cardiovascular disease and type 2 diabetes [3,4]. A striking increase in the number of people with the MS has taken place worldwide not only in developed countries but also in developing countries considerably due to changing environment and lifestyle [5]. Previous studies have showed that MS and cardiovascular diseases are more common in women above 55 years of age with significant increase in individual risk factors in the postmenopausal phase [6,7]. Changing hormonal milieu with decreasing estrogen and alteration of its ratio with testosterone has been implicated as a causal factor for the emergence of MS at menopausal

* Correspondence: jsubrina@hdrcrp.org

1Health & Disease Research Center for Rural Peoples (HDRCRP), 14/15, 1st Floor, Probalo Housing Ltd., Shekertak (Adjacent to Shekertak Road 1), Mohammadpur, Dhaka 1207, Bangladesh

2National Center for Global Health and Medicine (NCGM), 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

Full list of author information is available at the end of the article

© 2013 Jesmin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
transition [8,9]. Besides menopausal hormonal changes, aging also play roles to clustering of cardio-metabolic risk factors [10]. Questions remain whether menopause has a causative contribution to the deteriorating metabolic profile that is independent of chronological aging.

Prevalence of MS among pre- and post-menopausal women has varied according to different population. To date, several previous studies found a significance difference in prevalence of MS among pre- and post-menopausal women [11-17]. However, studies related to MS and menopausal status is limited in South Asia [14]. South Asian women, in general are to have MS at a younger age and have severe morbidity and mortality consequences as compared to Caucasians and other Asians [18,19]. Several studies found that menopausal status is influentially linked to some features of MS [11,14,16]. However, data on the empirical study of MS in Bangladesh are very rare. So far no studies have been conducted in Bangladesh to determine the prevalence of MS among pre- and post-menopausal women who are mostly poor and have limited or no access to health care services. In our previous studies we found that prevalence of metabolic syndrome was nearly 31% among rural women in Bangladesh, more than 85% rural women have low HDL cholesterol and nearly 31% have high fasting blood glucose [20,21]. Thus, it becomes necessary to measure prevalence of MS in Bangladeshi rural women focusing menopausal status for taking an early lifestyle interventions and treatment to prevent many non-communicable diseases in rural population as they are now confronting with an emerging health epidemic of MS. Thus, the objective of this study is to estimate the prevalence of MS in Bangladeshi rural women considering their menopausal status and further examined the association between menopausal status and MS and its components.

Methods

Study procedure and subjects

In a community based cross-sectional study of rural women, a total of 1802 participants aged ≥15 years were selected using stratified multistage random sampling. This sample size was sufficient to test all the research hypotheses at the 5% level of significance with a power of 80% ($\beta = 0.20$). Subjects were excluded having chronic illness such as hypothyroidism, pregnant women, those on hormone replacement therapy (HRT) as well as women with known illness such as ischaemic heart disease (IHD), diabetes and hypertension. The study uses the World Health Organization's STEPS approach (modified) which entails stepwise collection of the risk factor data based on standardized questionnaires covering demographic characteristics, somatic illnesses, somatic and mental symptoms, medications, life style, and health-related behavior (step 1), basic physical measures (step 2) and basic biochemical investigations such as blood glucose and cholesterol (step 3). Women were defined as post-menopausal if they had reported their last menses to be at least 12 months previously; pre-menopausal if they had an unchanged and regular menstrual pattern during the last five years, without typical climacteric complaints; and peri-menopausal if last menses to be within or before 12 months and were not regular. In our study we excluded peri-menopausal women. A standard questionnaire on health and menopausal status written in the local language was used to identify the pre- and post-menopausal subjects.

The study was carried out in 4 village communities of Gabindagonj Upazilla (subdistrict) of Gaibandha district, a poor district of the northern division of Rajshahi, the poorest region of the country. The respondents were selected randomly after selecting division, district, Upazilla and villages. Women were recruited through local announcement (loudspeaker) at community level and surveyors visits. The details of the study procedure have been described before in our previous study [21,22]. In brief, for getting required information, the participants were interviewed and examined clinically at mobile examination centre and asked to provide a blood sample. The study was approved by the Ethical Committee of the Health and Disease Research Center of Rural Peoples (HDRCRP), Dhaka, Bangladesh. This study conformed to the principles outlined in the Helsinki Declaration, and all subjects gave their written informed consent before inclusion in the study.

Anthropometric measurements

Anthropometric measurements on individuals wearing light clothing and without shoes were conducted by well-trained examiners. Height was measured to the nearest 0.1 cm using the portable stadiometer. Weight was measured in the upright position to the nearest 0.1 kg using a calibrated balance beam scale. Body mass index (BMI) was calculated by dividing weight (kg) by height squared ($\text{m}^2$). Waist circumference measurements were taken at the end of normal expiration to the nearest 0.1 cm, measuring from the narrowest point between the lower borders of the rib cage and the iliac crest. Blood pressure was measured twice in the right arm in a sitting position using the standard mercury manometer and cuff, to the nearest 2 mmHg, with the initial reading taken at least 5 minutes after the subject was made comfortable, and again after an interval of 15 minutes. The average systolic and diastolic blood pressures were then estimated.

Biochemical analysis

Blood for biochemical analysis was obtained from the participants after 10–12 hours of an overnight fast. The
blood sample was collected using standard blood sample collection procedure. After venipuncture of blood the processed serum/plasma were immediately stored at HDRCRP main or sub-center offices. The serum was immediately separated by centrifugation, and the concentration of triglycerides [lipoprotein lipase method; Wako Chemicals, Tokyo, Japan], total cholesterol [Cholesterol E, Wako Pure Chemical Industries, Ltd. Osaka, Japan] and its fractions high-density lipoprotein (HDL) cholesterol [HDL cholesterol with the Determiner-L kit (Kyowa Co Ltd, Tokyo, Japan)] were ascertained. Fasting plasma glucose [glucose with the Hexokinase G-6-PDH kit (Wako Pure Chemical Industries Ltd, Osaka, Japan) were also measured. After labeling blood sample vials, a part of blood were transported to National Centre for Global Health and Medicine (NCGM), Japan for advanced biochemical assessment processing.

**Definition of metabolic syndrome and risk factors**
We defined the metabolic syndrome (MS) using the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) [23]. As detailed in the NCEP-ATP III report, participants having three or more of the five following criteria were defined as having the MS: high blood pressure (≥130/≥85 mmHg), elevated fasting blood glucose (≥110 mg/dL or ≥6.1 mmol/L), high tri-glyceride (≥150 mg/dL or ≥1.65 mmol/L), low high-density lipoprotein (HDL) cholesterol (<50 mg/dL or <1.30 mmol/L), and abdominal obesity, as measured by a waist circumference of ≥88 cm for women. Participants who currently reported using antihypertensive or antidiabetic medication (insulin or oral agents) were counted as having high blood pressure or elevated fasting blood glucose, respectively.

**Statistical analyses**
The clinical and laboratory characteristic of study population are presented according to pre- and post-menopausal women. The significant differences between pre- and post-menopausal women were assessed by using the Student’s “t” test for continuous variables and chi-square ($\chi^2$) test for categorical variables. Logistic regression analyses were used to assess the association between menopausal status and MS and each of its components. Two types of models were used. The first model was crude model without any adjustment and the second model was adjusted for age. Statistical significance was set at the conventional $P < 0.05$. All analysis were performed using statistical software STATA version 12.0 (Lakeway Drive, College Station, Texas USA).

**Result**
The clinical and laboratory characteristics of the study population stratified by menopausal status and MS are presented in Table 1. A total of 1802 subjects turned out for data analysis. There were 1094 pre-menopausal and 708 post-menopausal women (ratio 1:1.55); and their ages ranged from 15–85 (mean 39.98 ± 13.97) years. Figure 1 shows the age and menopausal status distribution of the study subjects. Most (45.20%) of the study subjects were in the 45–54 year age group. There were more pre-menopausal than post-menopausal women across all age groups. The pre-menopausal women were aged 15–51 years (mean 31.36 ± 9.24) while post-menopausal women were aged 32–85 years (mean 53.31 ± 8.49) ($P < 0.001$).

The prevalence of MS and metabolic risk factors are presented in Table 2. Prevalence of MS was 25.6% in our study, where 39.3% of post-menopausal and 16.8% of pre-menopausal women ($P < 0.001$).

Prevalece of metabolic risk factors including elevated fasting blood glucose, high blood pressures, and high tri-glycerides were significantly higher in post-menopausal women ($P < 0.001$). However, prevalence of low HDL cholesterol was significantly lower in post-menopausal women than pre-menopausal women ($P = 0.001$).

| Table 1 Means of clinical and laboratory characteristics of the subjects |
|------------------------|-----------------|-----------------|-----------------|---|
| Variable               | Overall (n = 1802) | Pre-menopause (n = 1094) | Post-menopause (n = 708) | P value |
| Age, years             | 39.98 ± 13.97    | 31.36 ± 9.24     | 53.31 ± 8.49     | <0.001 |
| BMI, kg/m$^2$          | 21.88 ± 3.97     | 21.87 ± 3.99     | 21.89 ± 3.94     | 0.95   |
| Waist circumference, cm| 76.83 ± 8.32     | 76.89 ± 8.54     | 76.73 ± 7.98     | <0.001 |
| Systolic blood pressure, mmHg | 116.93 ± 21.38 | 110.56 ± 17.95 | 126 ± 22.51 | <0.001 |
| Diastolic blood pressure, mmHg | 75.53 ± 10.78 | 73.00 ± 9.80 | 79.44 ± 11.07 | <0.001 |
| Fasting blood glucose, mmol/L | 6.22 ± 2.72 | 5.77 ± 2.12 | 6.91 ± 3.35 | <0.001 |
| Total cholesterol, mg/dL | 181.09 ± 72.32 | 176.15 ± 70.00 | 188.75 ± 75.18 | <0.001 |
| HDL cholesterol, mg/dL | 41.38 ± 30.47 | 37.34 ± 17.69 | 45.69 ± 43.20 | <0.001 |
| Triglyceride, mg/dL    | 130.02 ± 109.95 | 114.79 ± 92.64 | 153.60 ± 128.94 | 0.007  |

Values are Mean ± SD. BMI: Body mass index, HDL cholesterol: High-density lipoprotein cholesterol.
Table 3 shows odds ratio (OR) and 95% confidence interval (CI) of MS and each component of MS according to menopausal status. In unadjusted model the prevalence of MS was 3.14 times more likely (CI: 2.52-3.92) in post-menopausal women than pre-menopausal women ($P < 0.001$). After adjustment for age the association was slightly attenuated but remains statistically significant (OR: 1.78, CI: 1.26-2.51, $P = 0.001$). Prevalence of elevated fasting blood glucose, high blood pressures, and high triglycerides were also significantly higher but prevalence of low HDL cholesterol were significantly lower in post-menopausal women than pre-menopausal women even after adjustment for age ($P < 0.05$ for all).

**Discussion**

In this cross-sectional study of Bangladesh we compare prevalence of MS and risk variables of MS in pre- and post-menopausal women and also identified how these variables relate to one another. This is the first report in Bangladesh investigating the prevalence of MS and each component of MS risk factors among rural women according to their menopausal status.

The prevalence of MS was higher in post-menopausal (39.3%) women than pre-menopausal (16.8%) women in our study and this prevalence was more likely in post-menopausal women even after adjustment for age. Our findings are consistent with many of previous studies [11,13-16,24], where post-menopausal women have been found to be at higher risk of MS than pre-menopausal women. Ruan et al., found that the prevalence of MS was 34% among Chinese post-menopausal women [24]. According to a study of Western India the prevalence of MS was 45% among pre-menopausal women, whereas it was 55% among post-menopausal women [14].

**Table 2**: Frequency of metabolic risk factors and metabolic syndrome

| Risk factors                  | Overall n (%) | Pre-menopause n (%) | Post-menopause n (%) | $P$ value |
|------------------------------|--------------|---------------------|----------------------|-----------|
| BMI > 30 kg/m²                | 52 (2.9)     | 34 (3.11)           | 18 (2.56)            | 0.50      |
| Elevated waist circumference | 152 (8.46)   | 91 (8.32)           | 61 (8.68)            | 0.79      |
| High blood pressures          | 506 (28.16)  | 159 (14.53)         | 347 (49.36)          | <0.001    |
| Elevated fasting blood glucose| 636 (35.39)  | 287 (26.23)         | 349 (49.64)          | <0.001    |
| Low HDL cholesterol           | 1512 (84.14) | 972 (88.85)         | 540 (76.81)          | 0.001     |
| High triglyceride             | 530 (29.49)  | 262 (23.95)         | 268 (38.12)          | <0.001    |
| Metabolic Syndrome $^a$       | 460 (25.60)  | 184 (16.82)         | 276 (39.26)          | <0.001    |

BMI: Body mass index, HDL cholesterol: High-density lipoprotein cholesterol.

$^a$ Metabolic syndrome is defined as presence of at least 3 of the following criteria.

Elevated waist circumference (≥88 cm), high fasting blood glucose (≥110 mg/dL), high triglycerides (≥150 mg/dL), low-high-density lipoprotein (HDL) cholesterol (<50 mg/dL), high blood pressure; systolic blood pressure (SBP ≥ 130 mm Hg) or diastolic blood pressure (DBP ≥ 85 mm Hg).
another study of India, a prevalence of 22.2% in the pre-menopausal as compared to 32.2% in the post-menopausal group was reported [25]. Arguing menopause as an independent predictor of MS, Eshtiaghi et al., showed a prevalence of 53.5% MS in post-menopausal Iranian women, on the other hand it was only 18% in pre-menopausal women [13]. Taken together, post-menopausal women are more prone to have MS than pre-menopausal women in Bangladesh. The transition from pre- to post-menopausal may be associated with each feature of the MS. In our study metabolic risk factors including high blood pressures, high triglyceride, and elevated fasting blood glucose are significantly higher among post-menopausal women than pre-menopausal women. However, prevalence of low HDL cholesterol is significantly lower in post-menopausal women than pre-menopausal women. In agreement with the results of our study, many previous studies have reported higher concentrations of hypertension [11,15,26], hypercholesterolemia [15], hypertriglyceridemia [5], and elevated fasting blood glucose [11,15] among post-menopausal women than pre-menopausal women. The decreased prevalence of low HDL cholesterol among post-menopausal women than pre-menopausal women is supported by a previous study [27]. Nonetheless, lower prevalence of low HDL cholesterol among post-menopausal women than pre-menopausal women is at variance with other studies [11,15]. Further research is required to elucidate the inconsistencies among studies.

The emergence of metabolic risk factors in post-menopausal phase may be a direct result of ovarian failure with estrogen deficiency. Decrease in estrogen production is thought to be responsible for substantial proportion of increased cardio-metabolic risk factors in post-menopausal women. Changes in metabolic risk factors during pre- and post-menopause may be due to a combination of factors of the aging process. Although previous studies showed age as the predominant variable associated with increased prevalence of MS, but higher prevalence of MS among women >50 years compared with men of the same age has been reported [28]. In our study the association between menopausal status and each component of metabolic MS was not significantly changed even after adjustment for age, which implies that post-menopausal women were indeed at higher risk of having MS and cardiovascular diseases.

In our study we found no significant difference in obesity component including BMI and waist circumference. Our findings are consistent with two previous studies of India [14] and Iran [16]. In addition, in a Framingham study [29] no significant difference was detected between BMI of pre- and post-menopausal women. However, significant differences in central body fat and BMI among pre- and post-menopausal women have been found in many other studies [11,15]. During menopause the pattern of hormone secretion changes and gradually causes fat accumulation in visceral tissues of abdomen and as a result, central obesity. However, the literature to date is not clear as to menopause itself is directly associated with obesity. Results of our study demonstrated that although there was no significant difference in abdominal obesity, the risk of MS was more prevalent among post-menopausal women due to significant difference among other component of MS. Differences in socio-environmental and genetic factors, lifestyles, type of menopause (natural/surgical) could be some of the reasons for this variability.

To the best of our knowledge, our study is the first to demonstrate the prevalence of MS and its components among pre- and post-menopausal women in a low-income country like Bangladesh. One of the major strengths of the present study is that it is based on the largest community-based and comprehensive MS survey. However, our study has several limitations that need to be mentioned. First, an association derived from a
cross-sectional study does not necessarily indicate causality. Second, menopausal status was self-reported and could have recall bias. Third, our study may have selection bias during cases recruitment due to selection of rural women from lower socioeconomic class and may not be generalized to the whole Bangladeshi women.

Conclusions
In conclusion, the results of our study suggest that the prevalence of MS in post-menopausal women was significantly higher than pre-menopausal women. Low HDL cholesterol, elevated fasting blood glucose, and high blood pressures were the most frequent features in comparison to the others. Prevention through changes in lifestyle, or early detection and treatment of elevated fasting blood glucose, hypertension, and hyperlipidemia are necessary for prevention of many chronic diseases in Bangladeshi women reaching after menopausal status. Health professionals should consider the post-menopausal women as a major target group for prevention of MS, which is an underlying condition of many non-communicable diseases.

Abbreviations
MS: Metabolic syndrome; BMI: Body mass index; HDL cholesterol: High-density lipoprotein cholesterol.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
SJ developed the idea for this paper, wrote the first draft of the manuscript and extensively edited the manuscript; AMSI and SA contributed to statistical analysis and writing results; MML and SNS performed all searches and compiled the text; NY, MH, MM and TW provided conceptual and editorial input. All authors equally contributed to discussion and approved the final version of manuscript.

Acknowledgements
The authors thank the study subjects for their cooperation and participation. This work was supported in part by a Grant-in-Aid for Scientific Research (overseas academic) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22406025) and Japan Society for the promotion of Science. A part of this work has also been supported by research grant from Uehara Memorial Foundation (Japan).

Author details
1Health & Disease Research Center for Rural Peoples (HDRCP), 14/15, 1st Floor, Probol Housing Ltd., Sheekhpat (Adjacent to Sheekhtak Road 1), Mohamadpur, Dhaka 1207, Bangladesh. 2National Center for Global Health and Medicine (NCGM), 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan. 3Department of Public Health, Tokai University Graduate School of Medicine, Isehara, Japan. 4Graduate School of Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305-8575, Japan.

Received: 31 August 2012 Accepted: 12 April 2013 Published: 18 April 2013

References
1. Bleich SN, Koehlimoo TL, Rashid M, Peters DH, Anderson G: Noncommunicable chronic disease in Bangladesh: overview of existing programs and priorities going forward. Health Policy 2011, 100:282–289.
2. World Health Organization (WHO): Noncommunicable Diseases Country Profiles. Geneva: WHO; 2011.
3. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poitier P, Rifnret S, Schiffin EL, Eisenberg MJ: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113–1132.
4. Ford ES, Li C, Sattar N: Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008, 31:1896–1904.
5. Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome: prevalence in worldwide populations. Endocrinol Metab Clin North Am 2004, 33:351–375.
6. Mesch VR, Boero LE, Siesies NO, Royer M, Prada M, Sayegh F, Schreier L, Benencia HJ, Berg GA: Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. Climacteric 2006, 9:40–48.
7. Lejaková M, Alušik S, Suchánek M, Zecová S, Pitha J: Menopause: clustering of metabolic syndrome components and population changes in insulin resistance. Climacteric 2011, 14:83–91.
8. Mesch VR, Siesies NO, Maidana PN, Boero LE, Sayegh F, Prada M, Royer M, Schreier L, Benencia HJ, Berg GA: Androgens in relationship to cardiovascular risk factors in the menopausal transition. Climacteric 2008, 11:509–517.
9. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K: Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med 2008, 168:1568–1575.
10. Moebus S, Baljepalli C, Lósch C, Góres L, von Stritzky B, Bramlage P, Wasem J, Jöckel KH: Age- and sex-specific prevalence and ten-year risk for cardiovascular disease of all 16 risk factor combinations of the metabolic syndrome - A cross-sectional study. Cardiovasc Diabetol 2010, 9:34.
11. Lin WY, Yang WS, Lee LT, Chen CY, Liu CS, Lin CC, Huang KC: Insulin resistance, obesity, and metabolic syndrome among non-diabetic pre- and postmenopausal women in North Taiwan. Int J Obes 2006, 30:912–917.
12. Any E, Mirmiran P, Zahedi Ad S, Azizi F: Prevalence of metabolic syndrome during menopause transition in Iranian women. Tehran Lipid and Glucose Study (TLGS). Maturitas 2007, 58:120–135.
13. Eshlighi R, Estegharnia A, Nakhjavani M: Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010, 65:262–266.
14. Pandey S, Srinivas M, Agasthe S, Joshi J, Galvanke P, Prakesam CP, Vaidya R: Menopause and metabolic syndrome: A study of 498 urban women from western India. J Midlife Health 2010, 1:51–69.
15. Ibrahimpour P, Fakhrazhadeh H, Heshmat R, Ghodsi M, Bandarian F, Larijani B: Metabolic syndrome throughout the menopausal transition. Menopause 2008, 15:505–515.
16. Heidari R, Sadeghi M, Taleai M, Rabiei K, Mohammadiard N, Sarrafzadegan N: Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetol Metab Syndr 2010, 2:189.
17. Zvirkovik TS, Yuksanovic M, Jelic MA, Sojjanovic J, Burić B, Jojić B, Milic N, Vajovic S: Obesity and metabolic syndrome during the menopause transition in Serbian women. Climacteric 2011, 14:634–648.
18. Misra A, Khurana L: The metabolic syndrome in South Asians: epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009, 7:497–514.
19. Pan WH, Yeh WT, Weng LC: Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr 2008, 17:37–42.
20. Jesmin S, Mia S, Islam AM, Islam R, Sultana SN, Zaedi S, Yamaguchi N, Okazaki O, Moroi M, Kimura S, Hiroe M: Prevalence of metabolic syndrome among rural Bangladeshi women. Diabetes Res Clin Pract 2012, 95(1):e7–e9.
21. Jesmin S, Islam MR, Islam AM, Mia MS, Sultana SN, Zaedi S, Yamaguchi N, Ishiwama Y, Hiroe M, Watanabe T: Comprehensive assessment of metabolic syndrome among rural Bangladeshi women. BMC Public Health 2012, 12:49.
22. Akter S, Jesmin S, Islam M, Sultana SN, Okazaki O, Hiroe M, Moroi M, Mizutani T: Association of age at menarche with metabolic syndrome and its components in rural Bangladeshi women. Nutr Metab (Lond) 2012, 9(1):99.
23. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F: Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735–2752.
24. Ruan X, Jin J, Hua L, Liu Y, Wang J, Liu S: The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it: Menopause 2010, 17(3):566–570.
25. Shah D. The Annual conference of the British Menopause Society. J Mid Life Health 2010, 1:48–50.

26. Figueiredo Neto JA, Figueirêdo ED, Barbosa JB, Barbosa Fde F, Costa GR, Nina VJ, Nina RV. Metabolic syndrome and menopause: cross-sectional study in gynecology clinic. Arq Bras Cardiol 2010, 95:339–345.

27. Feng Y, Hong X, Wilker E, Li Z, Zhang W, Jin D, Liu X, Zang T, Xu X, Xu X. Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. Atherosclerosis 2008, 196:590–597.

28. Man KH, Jong P, Yeon R, Jongoh K. The effect of menopause on the metabolic syndrome among Korean women. Diabetes Care 2007, 30:701–706.

29. Razy G, Heaton KW, Bolton CH. Coronary heart disease risk factors in relation to the menopause. Q J Med 1992, 85(2–3):889–896.

doi:10.1186/1756-0500-6-157
Cite this article as: Jesmin et al. Metabolic syndrome among pre- and post-menopausal rural women in Bangladesh: result from a population-based study. BMC Research Notes 2013 6:157.